Share to:

 

Nesvacumab

Nesvacumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetAngiopoietin 2
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6440H9966N1722O2008S38
Molar mass144860.89 g·mol−1

Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2.[1][2] As of May 2017, it is in Phase II clinical trials for the treatment of diabetic macular edema.[3][4]

This drug is being developed by Regeneron Pharmaceuticals.[citation needed]

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.
  2. ^ Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA (October 2019). "Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease". Expert Opinion on Investigational Drugs. 28 (10): 861–869. doi:10.1080/13543784.2019.1667333. PMID 31513439.
  3. ^ Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
Kembali kehalaman sebelumnya